Automated and Closed Cell Therapy Processing Systems Market Size, Share, Trends and Forecast 2024-2032
Market Scope
The Automated and Closed Cell Therapy Processing Systems Market is experiencing remarkable expansion as the biopharmaceutical industry increasingly shifts toward advanced cell-based therapies. Valued at approximately USD 1.43 billion in 2024, the market is projected to reach nearly USD 5.42 billion by 2032, registering a CAGR of 19.8% during the forecast period.
Automated and closed processing systems are designed to streamline cell isolation, expansion, genetic modification, harvesting, fill-finish operations, and cryopreservation within sterile and controlled environments. These technologies significantly reduce the risks associated with manual handling, including contamination, batch variability, and operational inefficiencies. Their ability to maintain compliance with Good Manufacturing Practice (GMP) standards makes them highly valuable for manufacturing therapies such as CAR-T, stem cell therapies, and gene-modified treatments.
The scope of the market extends across pharmaceutical companies, biotechnology firms, contract manufacturing organizations, and research institutions that are seeking scalable production capabilities to support the growing commercialization of personalized medicines.
Click to Request a Sample of this Report for Additional Market Insights: https://rnpmarketresearch.com/request-sample/automated-and-closed-cell-therapy-processing-systems-market-global-size-trends-competitive-and-historical-forecast-analysis-2024-2032
Recent Developments
The industry has witnessed several noteworthy developments aimed at improving manufacturing efficiency and expanding production capacity.
In April 2025, Cellino entered into a strategic partnership with Karis Bio to develop clinical-stage autologous induced pluripotent stem cell (iPSC)-based therapies for cardiovascular diseases. The collaboration leverages Cellino's Nebula™ autonomous biomanufacturing platform, which enables scalable and reproducible cell production within a closed manufacturing environment.
Similarly, in January 2025, Genenta Science expanded its partnership with AGC Biologics by securing access to a dedicated GMP manufacturing suite in Milan, Italy. The expansion is expected to support ongoing clinical studies and facilitate increased production of autologous cell therapies.
These advancements demonstrate the industry's commitment to enhancing automation capabilities while ensuring regulatory compliance and manufacturing consistency.
Market Drivers
One of the primary factors driving market growth is the increasing demand for scalable and GMP-compliant manufacturing solutions. The growing number of approvals for advanced therapies, including CAR-T products, stem cell therapies, and gene-engineered medicines, has intensified the need for reliable production systems.
Traditional open and manually operated manufacturing processes are often associated with labor-intensive procedures, high operating costs, and increased contamination risks. Automated platforms address these challenges by standardizing workflows and improving process reproducibility.
Another important growth driver is the rising number of strategic partnerships among biotechnology companies, pharmaceutical manufacturers, and technology developers. Collaborative initiatives enable companies to combine technical expertise, manufacturing infrastructure, and financial resources, accelerating the commercialization of innovative therapies.
The launch of automated solutions, such as Thermo Fisher Scientific's Gibco CTS Cellmation System, further highlights the industry's focus on enhancing manufacturing productivity and reducing human intervention.
Market Restraints
Despite significant growth prospects, several challenges continue to restrain market expansion.
Regulatory complexity remains one of the most prominent barriers. Automated manufacturing systems must undergo extensive validation and demonstrate their ability to consistently produce high-quality therapeutic products. Regulatory agencies require comprehensive documentation, comparative studies, and process verification before approving new manufacturing technologies.
The lengthy approval timelines associated with advanced manufacturing platforms can delay product commercialization and increase development costs. Smaller biotechnology firms may face difficulties in absorbing these expenses, limiting their ability to adopt highly sophisticated processing systems.
Additionally, substantial capital investments required for facility upgrades, equipment installation, and workforce training can create financial constraints for emerging companies.
Market Opportunities
The integration of artificial intelligence (AI), machine learning, and robotics into cell therapy manufacturing presents substantial growth opportunities.
AI-driven analytical tools can monitor production parameters in real time, identify deviations, optimize cell culture conditions, and enhance overall process control. Robotic systems can automate repetitive procedures such as media exchange, sample handling, and cell expansion, reducing human error and improving manufacturing consistency.
These technological innovations have the potential to bridge the gap between personalized medicine and large-scale commercial production, making advanced therapies more accessible and cost-effective for patients worldwide.
Geographical Analysis
North America currently dominates the market due to its well-established biotechnology ecosystem, favorable regulatory environment, and strong investment in advanced therapeutic development. The region continues to benefit from the expansion of automated manufacturing facilities and increasing clinical activity.
Europe represents another important market, supported by growing investments in GMP-compliant infrastructure and collaborations among leading biotechnology companies.
Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by rising healthcare investments, government initiatives, and expanding cell therapy research activities in countries such as Japan, China, and India.
Latin America and the Middle East & Africa are gradually emerging as promising markets, supported by infrastructure development and partnerships with global biomanufacturing organizations.
Browse Full Report: https://rnpmarketresearch.com/reports/automated-and-closed-cell-therapy-processing-systems-market-global-size-trends-competitive-and-historical-forecast-analysis-2024-2032
Market Segmentation
The Automated and Closed Cell Therapy Processing Systems Market is segmented by cell therapy type, workflow, scale, and geography.
By cell therapy type, the market includes stem cell therapy and non-stem cell therapy. Based on workflow, it comprises separation, expansion, apheresis, fill-finish processes, and cryopreservation. By scale, the market is categorized into pre-commercial or research and development scale and commercial-scale manufacturing.
Market Key Players
- Beckman Coulter
- Becton Dickinson and Company
- BioSpherix
- Cellares Inc.
- Charles River Laboratories
- Corning Incorporated
- Cytiva
- Fresenius Kabi
- GE Healthcare
- Lonza
- Macopharma
- Merck KGaA
- Miltenyi Biotec
- Sartorius AG
- STEMCELL Technologies
- Terumo BCT
- Thermo Fisher Scientific
- ThermoGenesis Holdings
- Other emerging and regional participants
About Us
R&P Market Research is a reliable source of industry intelligence and strategic insights, offering high-quality, data-driven reports for informed decision-making across various sectors.
Their focus on accuracy, integrity, and client satisfaction has established them as a preferred research partner. They provide global market assessments, trend forecasting, and tailored consulting services to meet clients' specific goals.
Contact Us
PNRDIGI MARKET RESEARCH (OPC) PRIVATE LIMITED, INDIA
📧 Email: rnpmarketresearch@gmail.com 📞 Phone: 8975005378
🌐 Website: https://rnpmarketresearch.com
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian